会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明申请
    • NOVEL PROCESS FOR PREPARATION OF DULOXETINE HYDROCHLORIDE
    • 制备盐酸杜莫西汀的新方法
    • WO2008107911A2
    • 2008-09-12
    • PCT/IN2008000125
    • 2008-03-05
    • LUPIN LTDSIYAN RAJINDER SINGHGOHEL SUNIL KUMAR VINUBHAISINGH GIRIJ PAL
    • SIYAN RAJINDER SINGHGOHEL SUNIL KUMAR VINUBHAISINGH GIRIJ PAL
    • C07D333/20
    • C07D333/20
    • An improved, safer and easy to operate on plant scale process for synthesis of duloxetine hydrochloride (1) having chiral purity greater than 99.9% that is characterized by the following: (i) preparation of racemic condensed compound (RS)-N,N-di methyl-3- (1-naphthyloxy)-3-(2-thienyl)propanamine (4) by reaction of racemic hydroxy compound (2) with 1-fluronaphthalene (3) in presence of a base such as sodamide, potassium amide or potassium bis(trimethylsilyl)amide (KHDMS) in polar aprotic solvent, (ii) optical resolution of racemic condensed compound (5a + 5b) with di-benzoyl-L-tartaric acid (7, DBTA, R = H) or di-para-anisoyl-L-tartaric acid (7, DATA, R = OCH3) to obtain crude (S)-N.N-dimethyl-3-(1-naphthyloxy)-3-(2-thienyl)propanamine dibenzoyl tartarate salt (8a) or (S)-N.N-dimethyl-3-(1-naphthyloxy)-3-(2-thienyl)propanamine di-p-anisoyl tartarate salt (9a) respectively, (iii) optionally purification of crude tartarate salts (8a or 9a) by crystallization, (iv) optionally purification of duloxetine hydrochloride (1) by crystallization and (v) racemization of undesired (R)-N,N-di methyl-3-(1-naphthyloxy)-3-(2-thienyl)propanamine (5b) by treatment with base potassium bis(trimethylsilyl)amide (KHDMS) to obtain racemic mixture of condensed compounds (5a and 5b). A novel salt S(+)-N.N-dimethyl-3-(1-naphthylenyloxy)-3-(2-thienyl)propanamine dibenzoyl -(L)- tartarate (8a) and S(+)-N.N-dimethyl-3-(1-naphthylenyloxy)-3-(2-thienyl)propanamine di-p-anisoyl-(L)- tartarate (9a). Novel process for racemization of undesired (R)-N,N-di methyl-3-(1-naphthyloxy)-3-(2-thienyl)propanamine (5b) by treatment with KHDMS to obtain racemic mixture condensed compounds (5a and 5b).
    • (1)手性纯度大于99.9%的度洛西汀盐酸盐(1)的合成工艺改进,更安全且易于操作,其特征在于:(i)制备外消旋缩合化合物(RS)-N, 通过使外消旋羟基化合物(2)与1-氟萘(3)在碱如氨基磺酸钠,氨基钾或碱土金属的存在下反应,制备2-甲基-3-(1-萘氧基)-3-(2-噻吩基)丙胺 (二甲基甲硅烷基)氨基钾(KHDMS)在极性非质子溶剂中的溶液,(ii)用二苯甲酰基-L-酒石酸(7,DBTA,R = H)或二 (S)-NN-二甲基-3-(1-萘氧基)-3-(2-噻吩基)丙胺二苯甲酰基酒石酸盐(8a)或(S)-N,N-二甲基-3- (S)-NN-二甲基-3-(1-萘氧基)-3-(2-噻吩基)丙胺二 - 对甲氧基苯甲酰基酒石酸盐(9a),(iii)任选纯化粗酒石酸盐(8a或9a) 通过结晶,(iv)任选纯化 盐酸度洛西汀(1)通过结晶和(v)通过用碱性钾处理不希望的(R)-N,N-二甲基-3-(1-萘氧基)-3-(2-噻吩基)丙胺 (三甲基甲硅烷基)酰胺(KHDMS)以获得缩合化合物的外消旋混合物(5a和5b)。 (+) - NN-二甲基-3-(1-萘基氧基)-3-(2-噻吩基)丙胺二苯甲酰基 - (L) - 酒石酸盐(8a)和S(+) - NN-二甲基-3- (1-萘基氧基)-3-(2-噻吩基)丙胺二 - 对甲氧基苯甲酰基 - (L) - 酒石酸盐(9a)。 用KHDMS处理外消旋不需要的(R)-N,N-二甲基-3-(1-萘氧基)-3-(2-噻吩基)丙胺(5b)的新方法以获得外消旋混合物缩合化合物(5a和5b )。
    • 10. 发明申请
    • AN IMPROVED PROCESS FOR THE MANUFACTURE OF LAMIVUDINE
    • 改进的制造方法
    • WO2008053496A2
    • 2008-05-08
    • PCT/IN2007/000399
    • 2007-09-10
    • LUPIN LIMITEDSINGH, Girij, PalSRIVASTAVA, DhananjaiSATYA, Srinivas, AyyalasomayajulaSAINI, Manmeet, BrijkishoreJADHAV, Harishchandra, SambhajiWARRIER, Aparna, MurlidharanDUMRE, Nilesh, Bhimsingh
    • SINGH, Girij, PalSRIVASTAVA, DhananjaiSATYA, Srinivas, AyyalasomayajulaSAINI, Manmeet, BrijkishoreJADHAV, Harishchandra, SambhajiWARRIER, Aparna, MurlidharanDUMRE, Nilesh, Bhimsingh
    • C07D411/04
    • An improved process for the manufacture of Lamivudine. The process involves preparation of racemic cis-(±)-Lamivudine of formula (XII), from a mixture of cis-(±) and trans-(±) intermediate of Formula (IX) by forming a crystalline salt and separating the Cis-(±)-Lamivudine from an organic solvent by fractional crystallization, the said process comprising the steps of: a. providing a mixture of the compound of Formula (IX) and an organic solvent; b. treating the mixture provided in step (a.) with an acid to form its corresponding salt, c. isolating the acid addition salt of the cis-(±) isomers of formula (X), by filtration, d. crystallizing the crude product, e. converting the salt obtained in step (d.) to its free base, f. deprotecting the free base obtained in step (e.) to the compound of Formula (XII). The process for the preparation of an optically pure or optically enriched enantiomer of cis-(-)-Lamivudine of formula (I), from a mixture of racemic cis-(±)-Lamivudine of formula (XII), the said process comprising the steps of: a. providing a mixture of cis-(±)-Lamivudine of Formula (XII) and an organic solvent; the said isomers having the following configurations [2R,5S] and [2S,5R], b. treating the mixture provided in step (a.) with a chiral host, c. isolating the adduct formed by the enantiomer and the chiral host, d. purifying the adduct formed in step (c.) with isopropanol containing a little amount of [S]- BINOL, e. treating the adduct with an acid to form its salt, f. neutralizing this salt using a base, thereby obtaining one of the enantiomers as optically pure Cis-(-)-Lamivudine of formula (I).
    • 改进的制备拉米夫定的方法。 该方法包括通过形成结晶盐从式(IX)的顺式 - (±)和反 - (±)中间体的混合物制备式(XII)的外消旋的顺式 - (±) - 咪达夫定, (±)-Lamivudine通过分级结晶从有机溶剂中提取,所述方法包括以下步骤:a。 提供式(IX)化合物和有机溶剂的混合物; 湾 用酸处理步骤(a)中提供的混合物以形成其相应的盐,c。 通过过滤分离式(X)的顺式(±)异构体的酸加成盐,d。 使粗产物结晶,例如, 将步骤(d)中获得的盐转化为游离碱,f。 将步骤(e)中获得的游离碱脱保护至式(XII)化合物。 从式(XII)的外消旋顺式 - (±) - 咪达夫定的混合物制备式(I)的顺式 - ( - ) - 拉米夫定的光学纯的或光学富集的对映异构体的方法,所述方法包括 步骤:a。 提供式(XII)的顺式 - (±) - 米夫定与有机溶剂的混合物; 所述异构体具有以下构型[2R,5S]和[2S,5R],b。 用手性主体处理步骤(a)中提供的混合物,c。 分离由对映异构体和手性主体形成的加合物,d。 用含少量[S] - BINOL的异丙醇纯化步骤(c)中形成的加合物, 用酸处理加合物以形成其盐,f。 使用碱中和该盐,从而获得一种对映异构体作为式(I)的光学纯的顺式 - ( - ) - 拉米夫定。